ANALYSING ASSOCIATION BETWEEN ANTHROPOMETRIC INDICATORS OF INSULIN RESISTANCE AND INSULIN-LIKE GROWTH FACTOR-1 IN PATIENTS WITH NODULAR GOITER

Authors

DOI:

https://doi.org/10.21856/j-PEP.2021.4.06

Keywords:

nodular goiter, anthropometric indicators, insulin resistance

Abstract

Publications suggesting that thyroid nodule might be associated with insulin resistance (IR) and metabolic syndrome are quite interesting. In a very recent report, increased thyroid volume and nodule prevalence were also reported in patients with IR in an iodine-sufficient area []. The purpose of the work is to analyze the association between anthropometric indicators IR and IGF-1 in patients with nodular goiter. 

Materials and methods. During the study the authors examined 73 patients with euthyroid single-node (n = 34) and multinodular goiter (n = 39) aged 17 to 74 years (mean - (51.0 ± 10.6) years), determining WC, WC / HC, BMI, WHtR, ABSI, BFD, BRI, CI, AVI, BAI, IGF-1, TSH, fT4, fT3. Thyroid volume, its structure, number, size and location of foci was assessed by an ultrasonic complex Aloka SSD-1100 (Japan), using a linear sensor 7.5 MHz.

 Results and their discussion. In the total number of patients with nodular goiter IGF-1 is nonlinearly negatively associated with BMI (r = -0.30; P = 0.016), WC (r = -0.26; P = 0.036), WHtR (r = -0.30) ; P = 0.020), AVI (r = -0.27; P = 0.03), ABSI (r = -0.31; P = 0.015), nonlinear positive with BFD (r = 0.27; P = 0.033) ), BRI (r = 0.29; P = 0.02) and linearly positive with BAI (r = 0.36; P = 0.004); thyroid volume is linearly positively associated with age (r = 0.35; P = 0.009), nonlinearly positively with WC / HC (r = 0.43; P = 0.001), BFD (r = 0.26; P = 0.06 ) and CI (r = 0.31; P = 0.02).

In patients with nodular goiter with BMI≥35 kg / m2 thyroid volume is linearly positively associated with BMI (r = 0.71; P = 0.049). In patients with nodular goiter with IRF-1 above the sex-age norm, thyroid volume is nonlinearly positively associated with WC / HC (r = 0.71; P = 0.01), BAI (r = 0.66; P = 0.03 ) and nonlinearly negative with BFD (r = -0.52; P = 0.01). It has been found that BAI explains 82.37% of the variance of IGF-1 in the general group and more than 90% of the variance of its level in groups of patients with nodular goiter with high IGF-1 with / without obesity. In patients with nodular goiter with high IGF-1 and obesity, the predictor of increased thyroid volume is BRI, which explains 81.14% of the variance of its volume.

 Conclusions: Patients with nodular goiter with IGF-1 level in blood above the sex-age norm have significantly higher values ​​of anthropometric indicators IR (WHtR, ABSI, BFD and BAI) compared with patients with a normal level of this indicator; in patients with nodular goiter with II degree obesity and above, thyroid volume is significantly associated with BMI; BAI (R2 = 82.37%) is a predictor of increased levels of IGF-1 in blood of patients with nodular goiter, regardless of the obesity; BRI (R2 = 81.14%) is a predictor of increased thyroid volume in patients with nodular goiter with IGF -1 high level and obesity.

Key words: nodular goiter, anthropometric indicators, insulin resistance

References

Pacini F, Schlumberger MJ. Pract Management Thyroid Cancer: 201-210. https://doi.org/10.1007/1-84628-013-3_17.

Hegedüs L. N Engl J Med 2004;351(17): 1764-1771. https://doi.org/10.1056/NEJMcp031436.

Reaven GM. Diabetes 1988;37(12): 1595-1607. https://doi.org/10.2337/diab.37.12.1595.

Sari R, Balci MK, Altunbas H, Karayalcin U. Clin Endocrinol (Oxf) 2003;59(2): 258-262. https://doi.org/10.1046/j.1365-2265.2003.01836.x.

Michalaki MA, Vagenakis AG, Leonardou AS, et al. Thyroid 2 006;16(1): 7 3-78. h ttps://doi.org/10.1089/thy.2006.16.73.

De Pergola G, Ciampolillo A, Paolotti S, et al. Clin Endocrinol (Oxf) 2007;67(2): 265-269. https://doi.org/10.1111/j.1365-2265.2007.02874.x.

Rezzonico J, Rezzonico M, Pusiol E, et al. Thyroid 2008; 18(4): 461-464. https://doi.org/10.1089/thy.2007.0223.

Van Keymeulen A, Dumont JE, Roger PP. Biochem Biophys Res Commun 2000;279(1): 202-207. https://doi.org/10.1006/bbrc.2000.3910.

Kimura T, Dumont JE, Fusco A, Golstein J. Eur J Endocrinol 1999;140(1): 94-103. https://doi.org/10.1530/eje.0.1400094.

Frittitta L, Sciacca L, Catalfamo R, et al. Cancer 1999; 85(2): 492-498. https://doi.org/10.1002/(SICI)1097- 0142(19990115)85:2%3C492::AID-CNCR30%3E3.0.CO;2-I.

Yasar HY, Ertuğrul O, Ertuğrul B, et al. Endocr Res 2011;36(4): 167-174. https://doi.org/10.3109/07435800.2011.593011.

Tsatsoulis A. J Clin Med 2018;7(3): 37. https://doi.org/10.3390/jcm7030037.

Răcătăianu N, Leach N, Bondor CI, et al. Arch Endocrinol Metab 2 017;61(6): 5 75-583. h ttps://doi.org/10.1590/2359-3997000000306.

Tang Y, Yan T, Wang G, et al. Int J Endocrinol 2017; 2017: 1617458. https://doi.org/10.1155/2017/1617458.

Clinkscales W, Ong A, Nguyen S, et al. Otolaryngol Head Neck Surg 2017;156(3): 472-479. https://doi.org/10.1177/0194599816685697.

Polymeris A, Papapetrou PD. Hormones (Athens) 2021; 13. https://doi.org/10.1007/s42000-021-00296-0.

World Health Organ. Оbesity: Preventing and managing the global epidemic. Report of a WHO consultation. Tech Rep Ser 2000: 894 p.

Krakauer NY, Krakauer JC. J Obes Weight Loss T her 2014;4: 216.

Krakauer NY, Krakauer JC. PLoS One 2012;7(7): e39504. https://doi.org/10.1371/journal.pone.003950.

Thomas DM, Bredlau C, Bosy-Westphal A, et al. Obesity (Silver Spring) 2 013;21(11): 2 264-2271. h ttps://doi.org/10.1002/oby.20408.

Valdez R. J Clin Epidemiol 1991;44(9): 955-956. https://doi.org/10.1016/0895-4356(91)90059-i.

Guerrero-Romero F, Rodríguez-Morán M. Arch Med Res 2 003;34(5): 4 28-432. https://doi.org/10.1016/S0188-4409(03)00073-0.

Bergman RN, Stefanovski D, Buchanan TA. Obesity 2011;19: 1083-1089. https://doi.org/10.1038/oby.2011.38.

Brunn J, Block U, Ruf G, et al. Dtsch Med Wochenschr 1981;106(41): 1338-1340. https://doi.org/10.1055/s-2008-1070506.

Feng J, et al. Am J Med Sci 2019;357(2): 116-123. https://doi.org/10.1016/j.amjms.2018.11.006.

Mohan S, Baylink DJ, Pettis JL. J Clin Endocrinol Metab 1996;81(11): 3817-3820. https://doi.org/10.1210/jcem.81.11.8923818.

Santisteban P, Acebrón A, Polycarpou-Schwarz M, Di Lauro R. Mol Endocrinol 1992;6(8): 1310-1307. https://doi.org/10.1210/mend.6.8.1406708.

Sousa PA, Vaisman M, Carneiro JR, et al. Endocrinol Metabol 2013;57(2): 120-125. https://doi.org/10.1590/s0004-27302013000200004.

Turcios S, Lence-Anta JJ, Santana JL, et al. Eur Thyroid J 2015;4(1): 55-61. https://doi.org/10.1159/000371346.

Kayastha P, Paudel S, Shrestha D, et al. J Institute Med 2010;32(2): 36-43.

Steinberger J, Jacobs DR, Raatz S. Int J Obes (Lond) 2005;29(11): 1346-1352. https://doi.org/10.1038/sj.ijo.0803026.

Lee MH, Lee JU, Joung KH, et al. Endocrinology 2015; 156(3): 1181-1193. https://doi.org/10.1210/en.2014-1670.

Hegedüs L, Bonnema SJ, Bennedbaek FN. Endocr Rev 2003;24(1): 102-132. https://doi.org/10.1210/er.2002-0016.

Downloads

Published

2021-12-03

How to Cite

Miroshnichenko О., Mykytyuk, M., Chernyavskay, I., Dubovyk, V., Seliukova, N., Dorosh, O., Gerasimenko, L., & Sazonov, M. (2021). ANALYSING ASSOCIATION BETWEEN ANTHROPOMETRIC INDICATORS OF INSULIN RESISTANCE AND INSULIN-LIKE GROWTH FACTOR-1 IN PATIENTS WITH NODULAR GOITER. Problems of Endocrine Pathology, 78(4), 40-49. https://doi.org/10.21856/j-PEP.2021.4.06

Issue

Section

CLINICAL ENDOCRINOLOGY